William Blair Reiterates Outperform Rating for Neumora Therapeutics (NASDAQ:NMRA)

William Blair restated their outperform rating on shares of Neumora Therapeutics (NASDAQ:NMRA) in a research report report published on Friday morning, RTT News reports.

Several other brokerages also recently commented on NMRA. JPMorgan Chase & Co. upped their price target on shares of Neumora Therapeutics from $20.00 to $22.00 and gave the company an overweight rating in a report on Monday, March 18th. Royal Bank of Canada reiterated an outperform rating and set a $31.00 price target on shares of Neumora Therapeutics in a report on Thursday, March 28th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Neumora Therapeutics has a consensus rating of Moderate Buy and a consensus price target of $22.57.

Neumora Therapeutics Stock Performance

Neumora Therapeutics stock opened at $11.19 on Friday. The company’s 50-day moving average price is $16.06 and its 200-day moving average price is $14.22. Neumora Therapeutics has a twelve month low of $9.35 and a twelve month high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Thursday, March 7th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.05. As a group, equities analysts forecast that Neumora Therapeutics will post -1.48 EPS for the current year.

Institutional Investors Weigh In On Neumora Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Amalgamated Bank purchased a new stake in Neumora Therapeutics in the 4th quarter valued at about $29,000. California State Teachers Retirement System purchased a new stake in Neumora Therapeutics in the 4th quarter valued at about $42,000. Tower Research Capital LLC TRC purchased a new stake in Neumora Therapeutics in the 4th quarter valued at about $44,000. Strs Ohio purchased a new stake in Neumora Therapeutics in the 4th quarter valued at about $54,000. Finally, SG Americas Securities LLC purchased a new stake in Neumora Therapeutics in the 4th quarter valued at about $108,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.